A method for enhancing learning ability and memory of patients with Alzheimers disease using mocetinostat is provided. The method includes administering an effective dose of mocetinostat into a subject in need. Based on the administration of mocetinostat, Aβ accumulation, Tau protein phosphorylation, and neuroinflammation can be reduced, and the level of synaptophysin and numbers of serotonergic neuron can be increased. Hence, the damage caused by the injection of oligomeric Aβ25-35 within hippocampal CA1 is relieved. The method may be a potential solution for relieving the symptoms of anxiety and cognitive impairment.
